University provides second dose of meningitis B vaccine

By Office of Communications on Feb. 17, 2014, 9:08 p.m.

This article was updated at 9:17 p.m. Thursday, Feb. 20.

Princeton University provided a second dose of the meningitis B vaccine to recommended campus groups Monday through Thursday, Feb. 17-20, with 4,404 individuals vaccinated by the end of the fourth day. Another 305 individuals received the second dose last month.

The first dose of the meningitis B vaccine has been provided to 5,471 individuals, representing 95 percent of the approximately 5,800 University community members who were eligible to receive the vaccine.

A second dose of the vaccine is needed for full immunity. Individuals who received only one dose of the vaccine at previous campus clinics are still at an increased risk of getting meningitis.

Students who had not yet received the first dose of the vaccine could do so Feb. 17-20, and will have an opportunity to receive the second dose at a later time.
 

Related Stories

UPDATE Dec. 12: More than 5,200 receive meningitis B vaccines .

Princeton University has provided the first dose of the meningitis B vaccine to 5,268 individuals, which represent 91 percent of the approximately 5,800 University community members who were eligible to receive the vaccine. Vaccinations were given during clinics in Frist Campus Center from Monday through Thursday, Dec. 9-12.

University researcher to conduct meningitis vaccine study .

A Princeton University researcher is recruiting students to participate in a study intended to learn more about the impact of the meningitis B vaccine that has been offered to members of the University community.

University provides meningitis B vaccine during campus clinics .

Princeton University began providing the first dose of the meningitis B vaccine to recommended campus groups on Monday, Dec. 9, with 1,959 individuals vaccinated by the end of the first day. At the conclusion of the clinics on Thursday night, the total number vaccinated was 5,268. The vaccine clinics are being held from noon to 8 p.m. Monday through Thursday, Dec. 9-12, in the Frist Campus Center multipurpose room.

No increased meningitis B risk at Princeton .

The Centers for Disease Control and Prevention (CDC) announced this week that the risk of meningitis B at Princeton University is the same as at any other university. Ninety-eight percent of Princeton undergraduates have received at least one dose of the meningitis B vaccine and there have been no cases of serogroup B meningococcal disease occurring on campus or affecting Princeton students since November 2013.

University will offer Meningitis B vaccines to recommended groups .

The Centers for Disease Control and Prevention (CDC) has now officially recommended that all Princeton University undergraduate students, and also graduate students living in undergraduate dormitories, the Graduate College and annexes, and other members of the University community with certain medical conditions, receive a vaccine that helps protect against meningococcal disease caused by serogroup B bacteria. The vaccine will be provided only to these groups, and it will not be administered anywhere else.

Student work: 'Princeton Against Meningitis' .

The Student Health Advisory Board speaks with some of the Princeton students who have had meningitis and with Dr. Janet Neglia of University Health Services. Eligible University community members who did not receive the Meningitis B vaccine in December 2013 may receive the first dose of the vaccine on Jan. 15-16 in the Frist Campus Center. A second dose of the vaccine will be available Feb. 17-20 in the Frist Campus Center. Two doses are needed for maximum protection. For more information visit the University's meningitis information website.

Meningitis B vaccine being considered at Princeton .

At the request of the New Jersey Department of Health (NJDOH), the Centers for Disease Control and Prevention (CDC) reviewed the seven cases of meningococcal disease contracted by Princeton University students and a student visitor since March 2013, all of which were caused by meningococcal bacteria known as serogroup B, including the latest case reported on Nov. 10.